Suda Pharmaceuticals Ltd. entered into an exclusive license agreement with Mitsubishi Tanabe Pharma Korea Co Ltd. for the rights to ZolpiMist for South Korea. The agreement is for an exclusive licence for and supply of ZolpiMist for South Korea with a term of ten years from first commercial sale. As part of the agreement, SUDA will receive an upfront fee of USD 0.1 million and a milestone payment based on MTPK obtaining regulatory approval of USD 0.1 million as well as commercial milestone payments based on MTPK achieving sales targets of the product up to a maximum series of milestone payments of USD 0.3 million. SUDA will also receive a double-digit royalty (12%) based on net sales of the product in the territory. SUDA to supply the product and receive a handling fee.